Bli medlem
Bli medlem

Du är här

2022-11-14

Nanexa receives approval to start clinical trial with NEX-20

Nanexa AB (publ) today announced that it has received approval from the Swedish Medical Products Agency to initiate a clinical trial of its drug candidate NEX-20, a long-acting formulation of lenalidomide, based on the PharmaShell® system, intended for the maintenance treatment of multiple myeloma cancer.

The study is a Phase 1 trial to study the pharmacokinetic profile, safety and tolerability of NEX-20, in ascending doses in healthy volunteers. Approval from the Ethics Review Board (etikprövningsnämnden) has already been obtained and other activities to start the study are on track.

"The approval is a major and important milestone for Nanexa as it is the first clinical study in the NEX-20 project. It means that we can now start the NEX-20 study on schedule and take our second drug based on PharmaShell into the clinic. We are now getting ready to start the study and expect to have the first results from the study in the first quarter of next year", says David Westberg.

For additional information, please contact:


David Westberg – CEO, Nanexa AB (publ) 
Phone: +46 70 942 83 03
Email: david.westberg@nanexa.se
www.nanexa.com
Erik Penser Bank is the company’s Certified Adviser and can be reached on +46 8 463 83 00, email: certifiedadviser@penser.se

About Nanexa AB (publ)


Nanexa is a pharmaceutical company developing injectable drug products based on the proprietary and innovative drug delivery system PharmaShell® – the high drug load delivery system enabling the next generation long-acting injectables through atomic layer precision. Nanexa develops its own products and also has collaboration agreements with several pharma companies, among others AstraZeneca.

Nanexa’s share is listed on Nasdaq First North Growth Market in Stockholm (NANEXA).

Attachments


Nanexa receives approval to start clinical trial with NEX-20

Författare MFN